A clinical trial to evaluate the safety and efficacy of Ataluren versus placebo in people who have specific genetic disease Duchenne Muscular Dystrophy

• Register: EUCTR
• Last refreshed on: 19 October 2020
• Main ID: EUCTR2017-001223-49-PL
• Date of registration: 05/06/2018
• Prospective Registration: Yes
• Primary sponsor: PTC Therapeutics, Inc.
• Public title: A clinical trial to evaluate the safety and efficacy of Ataluren versus placebo in people who have specific genetic disease Duchenne Muscular Dystrophy
• Scientific title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
• Target sample size: 340
• Recruitment status: NA
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001223-49
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes; Randomised: yes; Open: no; Single blind: no; Double blind: yes; Parallel group: no; Cross over: no; Other: no; If controlled, specify comparator, Other Medicinial Product: no; Placebo: yes; Other: no; Number of treatment arms in the trial: 2
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

Argentina, Australia, Brazil, Bulgaria, Canada, China, Hong Kong, India, Japan, Jordan, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Taiwan, Thailand, Turkey, United States

Contacts

• Name: Wendy Van den Branden
• Affiliation: Medpace, Inc.

• Name: Wendy Van den Branden
• Affiliation: Medpace, Inc.

Key inclusion & exclusion criteria

Inclusion criteria:
1. Evidence of signed and dated informed consent/assent document(s) indicating that the subject (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial. Note: If the study candidate is considered a child under local regulation, a parent or legal guardian must provide written consent prior to initiation of study screening procedures and the study candidate may be required to provide written
assent. The rules of the responsible institutional review board/ethics committee
(IRB/EC) regarding whether one or both parents must provide consent and the appropriate ages for obtaining consent and assent from the subject should be followed.
2. Male sex.
3. Age =5 years. When Version 3 is implemented or approximately 270 subjects have enrolled in the study, only subjects aged =7 to =16 who meet the mITT criteria will be eligible to enroll.
4. Phenotypic evidence of DMD based on the onset of characteristic clinical symptoms or signs (eg, proximal muscle weakness, waddling gait, and Gowers’ maneuver) by 6 years of age and an elevated serum creatine kinase (CK). Medical documentation of phenotypic evidence of DMD needs to be provided upon request by the PTC Therapeutics medical monitor.
5. Documentation of the presence of a nonsense point mutation in the dystrophin gene as determined by gene sequencing. Note: Review and approval of documentation by sponsor or designee is required prior to enrollment.
6. Use of systemic corticosteroids (prednisone/prednisolone or deflazacort) for a minimum of 12 months immediately prior to start of study treatment, with no significant change in dosage or dosing regimen for a minimum of 3 months immediately prior to start of study treatment and a reasonable expectation that dosage and dosing regimen will not change significantly for the duration of the study. Note: Daily, every other day, high-dose weekend, and intermittent regimens permitted only. The doses recommended or required are shown in Table 1. Increases in corticosteroid dose to adjust for increases in body weight will not exclude a subject from participation.
7. 6MWD =150 meters at screening, baseline Day 1, and baseline Day 2. When Version 3 is implemented or approximately 270 subjects have enrolled in the study, only subjects who meet the mITT criteria, 6MWD = 300 meters at Baseline Day 1 or Day 2, and time to stand from supine =5 seconds at Baseline Day 1, will be eligible to enroll. Note: Personal assistance or use of assistive devices for ambulation (eg, short leg braces, long leg braces, or walkers) will not be permitted during the 6MWT.
8. Results of the two Baseline 6MWD results must be determined as valid and results of the Day 2 Baseline 6MWD must be within 20% of the Day 1 Baseline 6MWD.
9. Baseline 6MWD (maximum of valid Day 1 and Day 2 values) must be no more than a 20% reduction from the valid Screening 6MWD.
10. Ability to perform timed function tests (run/walk 10 meters, climb 4 stairs, descend 4 stairs, stand from supine) within 30 seconds at screening and baseline.
11. In subjects who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug
administration and 4-week follow-up period.
12. Willingness and ability to comply with scheduled visits, drug administration plan,
study procedures, laboratory tests, and study restrictions. Note: Psychological, social, familial, or geographical facto
Exclusion criteria:
1. Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or reinitiation) in prophylaxis/treatment for cardiomyopathy within 1 month prior to start of study treatment.
2. Ongoing intravenous (IV) aminoglycoside or IV vancomycin therapy.
3. Prior or ongoing therapy with ataluren.
4. Known hypersensitivity to any of the ingredients or excipients of the study drug [eg, refined polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C,
crospovidone XL10, hydroxyethyl cellulose, colloidal silica, magnesium stearate].
5. Exposure to another investigational drug within 6 months prior to start of study
treatment, or ongoing participation in any interventional clinical trial. Note: This does not apply to patients receiving deflazacort through an expanded access program.
6. History of major surgical procedure within 12 weeks prior to start of study treatment,
or expectation of major surgical procedure (eg, scoliosis surgery) during the 72-week
placebo-controlled treatment period.
7. Ongoing immunosuppressive therapy (other than corticosteroids).
8. Requirement for daytime ventilator assistance or any use of invasive mechanical
ventilation via tracheostomy. Note: Evening non-invasive mechanical ventilation such as use of bi-level positive airway pressure (Bi-PAP) therapy is allowed.
9. Uncontrolled clinical symptoms and signs of congestive heart failure (American
College of Cardiology/American Heart Association Stage C or Stage D) [Hunt 2001].
10. Elevated serum creatinine or cystatin C at screening. Note: If the initial test result is
abnormal, it is permissible to re-test serum creatinine or cystatin C and randomize the subject if the re-test result is normal.
11. Positive for hepatitis B core antibody or hepatitis C antibody at screening.
12. Prior or ongoing medical condition (eg, concomitant illness, psychiatric condition,
behavioral disorder, alcoholism, drug abuse), medical history, physical findings (eg, lower-limb injury that may affect 6MWT performance), ECG findings, or laboratory
abnormality that, in the investigator’s opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.


Age minimum:
Age maximum:
Gender:
Female: no
Male: yes

Health Condition(s) or Problem(s) studied

Nonsense Mutation Duchenne Muscular Dystrophy
MedDRA version: 20.0 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disorders

Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]

Intervention(s)

Trade Name: Translarna 125 mg granules for oral suspension
Product Name: ataluren
Product Code: PTC124
Pharmaceutical Form: Granules in sachet
INN or Proposed INN: ATALUREN
CAS Number: 775304-57-9
Current Sponsor code: PTC124
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 125-
Pharmaceutical form of the placebo: Granules in sachet
Route of administration of the placebo: Oral use

Trade Name: Translarna 250 mg granules for oral suspension
Product Name: ataluren
Product Code: PTC124
Pharmaceutical Form: Granules in sachet
INN or Proposed INN: ATALUREN
CAS Number: 775304-57-9
Current Sponsor code: PTC124
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 250-
Pharmaceutical form of the placebo: Granules in sachet
Route of administration of the placebo: Oral use

Trade Name: Translarna 1000 mg granules for oral suspension
Product Name: ataluren
Product Code: PTC124
Pharmaceutical Form: Granules in sachet
INN or Proposed INN: ATALUREN
CAS Number: 775304-57-9
Current Sponsor code: PTC124
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1000-
Pharmaceutical form of the placebo: Granules in sachet
Route of administration of the placebo: Oral use

Primary Outcome(s)

Secondary Objective: • To determine the effects of ataluren on ambulation and burst activity as assessed by timed function tests
• To determine the effects of ataluren on lower-limb muscle function as assessed by the North Star Ambulatory Assessment (NSAA)
• To assess the safety profile of ataluren
• Evaluate the correlation between plasma concentration of ataluren and functional outcomes
? Evaluate the plasma pharmacokinetic (PK) profile of ataluren

Main Objective: To determine the effect of ataluren on ambulation and endurance as assessed by the 6-minute walk test (6MWT)

Primary end point(s): The primary endpoint of this study is slope of change in 6-minute walk distance (6MWD) over 72 weeks.

Timepoint(s) of evaluation of this end point: Screening, every 12 weeks for double-blind period, every 24 weeks for open-label period

Secondary Outcome(s)

Timepoint(s) of evaluation of this end point: Screening, every 12 weeks for double-blind period, every 24 weeks for open-label period

Secondary end point(s): Double-Blind Treatment Period:
• Change from baseline to Week 72 in 6MWD
• Composite of average change in times to run/walk 10 meters, climb 4 stairs, and descend 4 stairs at Week 72
• Change from baseline to Week 72 in time to run/walk 10 meters
• Change from baseline to Week 72 in time to climb 4 stairs
• Change from baseline to Week 72 in time to descend 4 stairs
• Change from baseline to Week 72 in NSAA total score
• Time to loss of ambulation over 72 weeks
• Time to loss of stair-climbing over 72 weeks
• Time to loss of stair-descending over 72 weeks
• Risk of loss of NSAA items over 72 weeks
• Ataluren safety profile characterized by type, frequency, severity, and relationship to study drug of any adverse events (AEs), or of abnormalities of laboratory tests, vital signs, physical examinations, or electrocardiograms (ECGs)

Open-Label Treatment Period:
• Slope of change in 6MWD over 144 weeks
• Change from baseline to Week 144 in 6MWD
• Composite of average change in times to run/walk 10 meters, climb 4 stairs, and descend 4 stairs at Week 144
• Change from baseline to Week 144 in time to run/walk 10 meters
• Change from baseline to Week 144 in time to climb 4 stairs
• Change from baseline to Week 144 in time to descend 4 stairs
• Change from baseline to Week 144 in NSAA total score
• Time to loss of ambulation over 144 weeks
• Time to loss of stair-climbing over 144 weeks
• Time to loss of stair-descending over 144 weeks
• Risk of loss of NSAA items over 144 weeks
• Ataluren safety profile characterized by type, frequency, severity, and relationship to study drug of any AEs, or of abnormalities of laboratory tests, vital signs, physical examinations, or ECGs

Secondary ID(s)

2017-001223-49-BG

PTC124-GD-041-DMD

NCT01826487

Source(s) of Monetary Support

PTC Therapeutics, Inc.